Logo

Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER2-Positive Early Breast Cancer in Japan

Share this

Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER2-Positive Early Breast Cancer in Japan

Shots:

  • The application is based on P-III KATHERINE study assessing Kadcyla as adjuvant therapy vs Herceptin in ~ 1-500 patients with HER2+ early breast cancer who had invasive residual disease in the breast or axillary lymph nodes following neoadjuvant therapy including Herceptin
  • The P-III KATHERINE study results: superiority in invasive disease-free survival as confirmed; no superiority in OS; well tolerated in patients with HER2+ early breast cancer. Chugai plans to expand its HER2 portfolio with the approval of the new indication
  • Kadcyla is a combination of Herceptin and CT medicine emtansine and has received FDA’s BT designation- an approved therapy in the US to treat HER2+ m-BC and & early-stage HER2+ BC after surgery- prior treated with Herceptin and Taxane CT

Click here to­ read full press release/ article | Ref: Chugai Pharmaceutical | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions